RxDoctor Payments Data

Ankur Gupta, MD

Cardiovascular Disease · Visalia, CANPI 1396990560

Payments from drug & device makers

$21,430in general payments, 2019–2025

Across 156 payments — averaging $137.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$10K
  • Medtronic$4K
  • Abbott$3K
  • Edwards Lifesciences$2K
  • Boston Scientific$701
  • Abiomed$230
  • plus $940 from 20 others

What the payments were for

  • Speaking & faculty fees$9,90046%
  • Travel & lodging$6,27029%
  • Food & beverage$5,26025%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,430 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$328,403
Medicare patients
1,062
Services billed
3,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$213,648
EntrestoSacubitril/Valsartan103$125,869
XareltoRivaroxaban53$58,987
Repatha SureclickEvolocumab35$43,949
FarxigaDapagliflozin Propanediol30$21,424
Praluent PenAlirocumab32$19,160
JardianceEmpagliflozin11$12,458
NexletolBempedoic Acid11$6,767
Ezetimibe157$6,683
Metoprolol Succinate405$5,705
Flecainide Acetate72$3,697
Atorvastatin Calcium316$2,746
Rosuvastatin Calcium214$2,707
Amiodarone Hcl78$2,317
Carvedilol202$1,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$213,648182 claims
NovartisEntresto$137$125,869103 claims
Johnson & JohnsonXarelto$25$58,98753 claims
Boehringer IngelheimJardiance$43$12,45811 claims
Esperion Therapeutics, Inc.Nexletol$20$6,76711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →